1. Home
  2. STTK vs SMID Comparison

STTK vs SMID Comparison

Compare STTK & SMID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • SMID
  • Stock Information
  • Founded
  • STTK 2016
  • SMID 1960
  • Country
  • STTK United States
  • SMID United States
  • Employees
  • STTK N/A
  • SMID N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • SMID Building Materials
  • Sector
  • STTK Health Care
  • SMID Industrials
  • Exchange
  • STTK Nasdaq
  • SMID Nasdaq
  • Market Cap
  • STTK 56.8M
  • SMID 166.5M
  • IPO Year
  • STTK 2020
  • SMID 1995
  • Fundamental
  • Price
  • STTK $1.12
  • SMID $39.43
  • Analyst Decision
  • STTK Hold
  • SMID
  • Analyst Count
  • STTK 3
  • SMID 0
  • Target Price
  • STTK $2.00
  • SMID N/A
  • AVG Volume (30 Days)
  • STTK 182.2K
  • SMID 22.1K
  • Earning Date
  • STTK 02-27-2025
  • SMID 11-14-2024
  • Dividend Yield
  • STTK N/A
  • SMID N/A
  • EPS Growth
  • STTK N/A
  • SMID 1025.92
  • EPS
  • STTK N/A
  • SMID 1.22
  • Revenue
  • STTK $6,435,000.00
  • SMID $76,366,000.00
  • Revenue This Year
  • STTK $313.04
  • SMID N/A
  • Revenue Next Year
  • STTK N/A
  • SMID N/A
  • P/E Ratio
  • STTK N/A
  • SMID $31.93
  • Revenue Growth
  • STTK 382.75
  • SMID 32.40
  • 52 Week Low
  • STTK $0.94
  • SMID $25.03
  • 52 Week High
  • STTK $11.76
  • SMID $51.96
  • Technical
  • Relative Strength Index (RSI)
  • STTK 43.75
  • SMID 37.98
  • Support Level
  • STTK $1.13
  • SMID $37.70
  • Resistance Level
  • STTK $1.39
  • SMID $40.20
  • Average True Range (ATR)
  • STTK 0.11
  • SMID 2.17
  • MACD
  • STTK 0.00
  • SMID -0.81
  • Stochastic Oscillator
  • STTK 18.18
  • SMID 17.40

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

Share on Social Networks: